newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - MEREO BIOPHARMA GROUP PLC

  • Financial Performance:

    • Projects full-year profitability in 2027, supported by a strong balance sheet with >$700M in cash following two PRV sales adding ~$350M.
    • 2024 R&D spend capped below $350M and SG&A below $375M to secure the path to profitability.
    • Base business of four programs growing >20% annually, with revenue expected to approach $1B in the coming year.
    • Implemented ~20% workforce reduction and 50% cut in R&D spending to optimize cost structure.
    • No intention to raise capital to achieve profitability; balance sheet is sufficient to fund operations.
  • Guidance and Future Outlook:

    • Financial guidance includes potential costs for a new Osteogenesis Imperfecta (OI) trial; current budget assumes another trial is required for approval.
    • Revenue growth for the four existing commercial programs expected to maintain >20% historical rates, driven by territory expansion (e.g., Japan, Middle East).
    • Does not provide specific revenue forecasts for new gene therapy launches (FiUV, GenGlycos) until ~6 quarters of post-launch data are available.
    • Aims to launch a next-generation version of Cris-feta by the time of the 2032 patent expiration.
    • Anticipates sustainable profitability beyond 2027, leveraging a focused pipeline and commercial leverage from existing infrastructure.
  • Business Segments and Product Lines:

    • Commercial Portfolio: Six approved products; strong performance from Dovolvi and Cris-feta, with Mepsevi and Kivexa also contributing.
    • Gene Therapy Launches: Two new products, FiUV (Sanfilippo syndrome) and GenGlycos (GSD1A), are performing well post-launch; patient uptake is rapid, particularly in Sanfilippo.
    • FiUV Launch: Estimated 300–400 treatable US patients; high urgency noted by patients and parents.
    • GenGlycos Launch: Estimated 1,600–2,000 treatable US patients; rollout expected to be slightly slower than FiUV.
    • Manufacturing: Company-owned AAV manufacturing facility in Massachusetts is fully inspected; capable of producing both current gene therapies and future programs, with capacity to expand via a second suite without building a new plant.
    • Pipeline: Continuing pursuit of OI program (Trut-Map) despite initial study miss; Phase 3 data for OTC gene therapy (301) shows strong ammonia control and functional improvement.
  • Market and Competitive Landscape:

    • OI Program: Trut-Map demonstrated significant bone mineral density (BMD) improvements (approx. 30% increase) and pain/physical function benefits; head-to-head data shows superiority over bisphosphonates in BMD metrics.
    • OTC Program: Data indicates patients previously deemed "stable" on standard of care experience dramatic cognitive and functional improvements once ammonia is controlled; market opportunity viewed as larger than Sanfilippo.
    • Competitive Advantage: Agnostic modality strategy (gene therapy, biologics, small molecules) with a focused high-value pipeline; unique ability to leverage existing commercial infrastructure for new inborn error therapies.
    • Market Trends: High patient urgency and demand for curative treatments in ultra-rare diseases driving immediate interest in new gene therapies.
  • Risks and Challenges:

    • Clinical Setbacks: Two recent clinical misses (Angelmann syndrome and initial OI Phase 3) have impacted stock price and necessitated restructuring.
    • Regulatory Uncertainty (OI): FDA has not yet accepted BMD as a predictive surrogate for OI approval; company faces potential requirement for a new confirmatory or prospective trial.
    • Trial Design Challenges: Difficulty enrolling high-fracture-rate patients in placebo-controlled OI trials due to ethical concerns regarding withholding standard bisphosphonate therapy.
    • Patient Retention: Challenges in transitioning OTC patients off existing medications and diets due to patient reliance on "security blankets" and fear of clinical crashes.
    • Patent Expiration: Cris-feta composition of matter patent expires around 2032, requiring life-cycle management strategy.
  • Management Commentary and Tone:

    • Confidence: Management expressed strong confidence in achieving 2027 profitability and long-term value creation despite recent setbacks.
    • Resilience: Acknowledged the "two misses" but emphasized a strategic pivot to a tighter, higher-value footprint and significant cost discipline.
    • Regulatory Approach: Optimistic about current FDA team (CBER/CEDA), describing them as rational, collaborative, and supportive of rare disease frameworks compared to prior administrations.
    • Transparency: Committed to providing launch metrics (treatment centers, forms, revenue) in January and maintaining standard guidance practices.
  • Analyst Questions and Answers:

    • Profitability Sustainability: Confirmed 2027 profitability is intended to be sustained; relies on base business growth and controlled R&D/SG&A.
    • R&D Allocation: Specific headcount split (R&D vs. H&A) not disclosed, but R&D budget supports commercial programs plus a focused set of trials (UX143, OI, OTC).
    • OI Trial Design: Discussed potential designs including a COSMIC-sized, head-to-head, active-comparator trial in high-fracture patients rather than a new placebo study.
    • Life Cycle Management: Strategy for Cris-feta involves collaborating with Kierman on next-generation molecules with improved potency or dosing frequency to mitigate LOE risk.
    • OTC Drug Development: Clarified that open-label data aims to demonstrate safety of discontinuing standard care, though blinded data already supports regulatory approval based on ammonia control.
  • Other Key Points:

    • Angelmann Syndrome: Program is being paused/set aside for the moment.
    • OI Subtypes: Trut-Map showed efficacy across OI Type 1, 3, and 4 subtypes, though Type 3/4 patients have deformed long bones which may limit structural healing despite BMD gains.
    • Patient Awareness: Highlighted that OTC patients often do not recognize their baseline impairment ("I was fine") until they experience the clarity provided by the therapy.
    • Regulatory Precedent: Cited the FiUV approval process (over two years of discussion on biomarkers) as an example of the time required for complex rare disease negotiations.
Company
MEREO BIOPHARMA GROUP PLC
Keywords
MEREO BIOPHARMA GROUP PLC